CA3044257A1 - Methods for cancer detection - Google Patents

Methods for cancer detection Download PDF

Info

Publication number
CA3044257A1
CA3044257A1 CA3044257A CA3044257A CA3044257A1 CA 3044257 A1 CA3044257 A1 CA 3044257A1 CA 3044257 A CA3044257 A CA 3044257A CA 3044257 A CA3044257 A CA 3044257A CA 3044257 A1 CA3044257 A1 CA 3044257A1
Authority
CA
Canada
Prior art keywords
biomarker
subject
cancer
gene
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3044257A
Other languages
English (en)
French (fr)
Inventor
Robert Feldman
Melanie MAHTANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRIME GENOMICS Inc
Original Assignee
PRIME GENOMICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRIME GENOMICS Inc filed Critical PRIME GENOMICS Inc
Publication of CA3044257A1 publication Critical patent/CA3044257A1/en
Pending legal-status Critical Current

Links

Classifications

    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3044257A 2016-11-22 2017-11-22 Methods for cancer detection Pending CA3044257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425549P 2016-11-22 2016-11-22
US62/425,549 2016-11-22
PCT/US2017/063157 WO2018098379A1 (en) 2016-11-22 2017-11-22 Methods for cancer detection

Publications (1)

Publication Number Publication Date
CA3044257A1 true CA3044257A1 (en) 2018-05-31

Family

ID=62195635

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3044257A Pending CA3044257A1 (en) 2016-11-22 2017-11-22 Methods for cancer detection

Country Status (8)

Country Link
US (1) US20200081008A1 (enExample)
EP (1) EP3544605A4 (enExample)
JP (2) JP2020511933A (enExample)
CN (1) CN110198711A (enExample)
CA (1) CA3044257A1 (enExample)
MA (1) MA46927A (enExample)
MX (1) MX2019006005A (enExample)
WO (1) WO2018098379A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044257A1 (en) * 2016-11-22 2018-05-31 Prime Genomics, Inc. Methods for cancer detection
CN108830045B (zh) * 2018-06-29 2021-04-20 深圳先进技术研究院 一种基于多组学的生物标记物系统筛选方法
KR102211972B1 (ko) * 2018-08-02 2021-02-04 엑소젠 피티이. 엘티디 액체생검 다중 암 유전자 바이오마커를 이용한 유방암 조기진단 및 치료 후 모니터링 방법
WO2020180896A1 (en) * 2019-03-03 2020-09-10 Purdue Research Foundation Systems and methods for identifying subtype, prognosis and monitoring of breast cancer
CN111679076A (zh) * 2020-06-15 2020-09-18 吉林医药学院 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒
US20210388451A1 (en) * 2020-06-16 2021-12-16 Grail, Inc. Methods for analysis of cell-free rna
CN111979321B (zh) * 2020-08-26 2022-07-12 郑州大学第一附属医院 用于胰腺癌检查的基因标记物
EP4208712A4 (en) * 2020-09-01 2024-12-11 Oncodea Corporation PREDICTIVE DIAGNOSTIC TEST FOR EARLY DETECTION AND MONITORING OF DISEASE
CN115927610B (zh) * 2022-07-19 2024-11-05 武汉艾米森生命科技有限公司 检测foxo6基因中目标区域的甲基化水平的试剂在制备膀胱癌诊断产品中的应用
WO2025005966A1 (en) * 2023-06-29 2025-01-02 Edge Animal Health, Inc. Urine pcr assay and use thereof to diagnose and stage feline chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6358683B1 (en) * 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
JP2008073304A (ja) * 2006-09-22 2008-04-03 Gifu Univ 超音波乳房診断システム
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2011100472A1 (en) * 2010-02-10 2011-08-18 The Regents Of The University Of California Salivary transcriptomic and proteomic biomarkers for breast cancer detection
CA2803266A1 (en) * 2010-07-08 2012-01-12 Prime Genomics, Inc. System for the quantification of system-wide dynamics in complex networks
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR101335034B1 (ko) * 2011-08-25 2013-12-02 주식회사 바이오인프라 유방암 진단을 위한 엑소좀 내의 ＡＮＴ2 ｍＲＮＡ의 이용방법
AU2015210886A1 (en) * 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2015187727A2 (en) * 2014-06-04 2015-12-10 Atossa Genetics Inc. Molecular mammography
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
CA3044257A1 (en) * 2016-11-22 2018-05-31 Prime Genomics, Inc. Methods for cancer detection

Also Published As

Publication number Publication date
MA46927A (fr) 2019-10-02
JP2020511933A (ja) 2020-04-23
EP3544605A4 (en) 2020-11-25
WO2018098379A1 (en) 2018-05-31
CN110198711A (zh) 2019-09-03
US20200081008A1 (en) 2020-03-12
MX2019006005A (es) 2019-10-02
EP3544605A1 (en) 2019-10-02
JP2022163076A (ja) 2022-10-25

Similar Documents

Publication Publication Date Title
US20200081008A1 (en) Methods for cancer detection
US20220325348A1 (en) Biomarker signature method, and apparatus and kits therefor
Galardi et al. Cell-free DNA-methylation-based methods and applications in oncology
JP6161607B2 (ja) サンプルにおける異なる異数性の有無を決定する方法
TW202124728A (zh) 核酸鹼基修飾的測定
US11814687B2 (en) Methods for characterizing bladder cancer
JP2019520791A (ja) ５−ヒドロキシメチル化無細胞系ｄｎａをシーケンシングすることによる非侵襲性診断
US20230368915A1 (en) Metastasis predictor
WO2019174004A1 (en) System and method for determining lung cancer
US20250101508A1 (en) Compositions and methods related to tet-assisted pyridine borane sequencing for cell-free dna
US20200040404A1 (en) Compositions and methods for detecting prostate cancer
US20240327930A1 (en) Compositions and methods for detecting prostate cancer
Lotem et al. Urine cf-nucleosomes: A non-invasive window into human physiology and disease
WO2026015665A1 (en) Determining methylation status of biological samples
WO2024137664A1 (en) Methods for detecting glioblastoma in extracellular vesicles
WO2025221865A1 (en) Methods and compositions for cell free rna modification analysis
JP2024534509A (ja) ｃｆＲＮＡおよびｃｆＴＮＡの標的ＮＧＳシーケンシングのための組成物および方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928